Clinical Pearls

Julie Carbray, PhD, PMHNP-BC, APRN, discusses how emerging therapies for bipolar disorder differ from traditional mood stabilizers, including improved tolerability and reduced side effects.

Julie Carbray, PhD, PMHNP-BC, APRN, provides an overview of some of the key cardiometabolic symptoms and adverse effects that clinicians should be on the lookout for in their patients with bipolar disorder.

Brittany Albright, MD, MPH, consultant, Psych Congress, and Kristian Dambrino, DNP, PMHNP-BC, consultant, Psych Congress, discuss common pitfalls when it comes to diagnosing MDD and TRD, as well as tools that clinicians have at their disposal...

Brittany Albright, MD, MPH, and Kristian Dambrino, DNP, PMHNP-BC,, discuss referral practices for esketamine and transcranial magnetic stimulation for patients with depression.

Brittany Albright, MD, MPH, and Kristian Dambrino, DNP, PMHNP-BC, discuss the difference between major depressive disorder and treatment-resistant depression, plus monoaminergic versus glutamatergic treatments.

In this video, Hara Oyedeji, APRN, PMHNP-BC, MSEd, offers guidance to APPs navigating LAI initiation while considering oral overlap requirements in the treatment of schizophrenia.

In part 2 of this series, Hara Oyedeji, APRN, PMHNP-BC, MSEd, unpacks the use and benefits of xanomeline-trospium as a treatment option for schizophrenia.

In this video, Hara Oyedeji, APRN, PMHNP-BC, MSEd, explores how APPs can most effectively prescribe and monitor patient progress on clozapine, the only FDA-approved treatment for treatment-resistant schizophrenia.

In part 1 of this series, Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, and Kristian Dambrino, DNP, PMHNP-BC, discuss the role NMDA and AMPA receptors play in rapid-acting depression treatment.

In this video, Craig Chepke, MD, DFAPA, discusses effective communication strategies clinicians can use when introducing long-acting injectable (LAI) antipsychotics to patients for the treatment of schizophrenia.